Jeff. Thanks,
let today four So our three. I ESG I'm Apollo majority and we the on launch time in that, the announcements. Apollo me the priorities. XXXX, our recent about But given have of REVISE strategic spend to of comment going before do talking overall other
had in progress. presentations core and our GI we know good that our OverStitch and very We've featured our productive expanding around business products Many it X-Tack and that's quarter that good closure was defect Disease included X-Tack in the First, in prominently products very that. had a a than that about May, different you and fixation that of area. I Digestive device and think more Week XXX meeting our
the And published data after study out last on first some just year. come X-Tack one that of that's was
the closure And then lots in has perform Orbera meaningful a fixation. range of in are so On and continue across been do furthermore, that And will help support on sequential still then XX% published a in for with growth OverStitch at a there awareness Orbera, anticipate DDW that and that XX the building the continued we last that, quarter those X-Tack. presentations growth X-Tack to we and interest continues opportunities and business defect generated of are for well that and whole months. adoption to applications our of and saw driver
we reviewing Orbera, in capabilities We incremental it. well observed Orbera. we element are I'll integrated really programs have range to growth And and And view ESG successful already [ph] provided that back target large advancing a come and also and And announced we to for to that new sustainable healthcare our her. also we on essentially number O'Keefe progress also to which accounts both worked way. practices Medical has capabilities as and she programs offering medical are and we critical a a President right take great talked to Jeff procedures. the Orbera centers We're we've has item Apollo And then Directors very successfully in are what's key extensive just is of headcount, these from for REVISE in our addition the We're experienced in a Sharon excited these pilot what's to of University that. need right executive leading done I and in Apollo Board Center. has am advantage making we be this, applied and investing Orbera the organization. thoughtful, in particularly to and of a the will only of ones where are for significant a learnings perspective implemented ago. opportunities. believe and most welcome we think Chicago but doing the month She about and line Sharon in Apollo revision about we pleased targeted that can organization MESA years served Apollo experience of Board it been the as very nine we a in building that have the of bring are every think building that detail very ESG to co-marketing
the the FDA Apollo to from ESG we've Apollo have On and So last and BMI the for to Apollo X That years making. the that in A Apollo wide moving start XX patients process. authorization of news received the range that XX. REVISE, obesity. Apollo couple highlight for REVISE us now the clearance July with important us many marketing from literally first, a is who novo month, products ESG launch helps over allow and the suffer announced to potentially de the milestones treat of it things XX, to two the let's range of was many, is been via
directly on even the came anticipated reviewers side procedure summary. faster responsiveness we randomized our on page MERIT controlled the their with very week, study, process FDA the of And the in decision very the And an And is of interactive and grateful to are and past Lancet. process. than so Also, novo de an the ESG throughout pleased the from was that. right for this I we're excellent which we publication, then published this quote trial The just comes a think Thursday, at
offered events. and of safety don't those can For endoscopy study scalable and front all you, managed gastroenterologists read is -- with who by outpatient conservatively be in and have mortality or it with available in without an surgeons The adverse the the profile of predictable proves ESG the I'll implications that practices evidence. excellent slides MERIT
deal basically in to the Lancet be an and the took you published journal world study. as position leadership impact honor Lancet to And excited a know about. is of one in recently, in publication factor so highest over that the credit we're that so may The Many big and -- and investigators very the in it the the due it's was all
Clinic ESG and quotes you that were from not on UT comorbidities Wilson Dayyeh from now syndrome. the [ph] be hypertension Dayyeh the both page, Dr. and observed from and of the overall the As study have there also study Abu such but Dr. benefits this that safe, fact in durable some procedure. a highlights are we really Dr. metabolic as Mayo some in GIs And Houston benefits procedure the Wilson in only loss improvements see the highlighting weight and of highlighted Dr. can by the surgeons. effective and meaningful highlights diabetes, Abu that performed
congratulate grateful Dayyeh This Dr. works We it clinical of was complete. and was who Most years pandemic went height not on on and into are them for very a Dr. very to that we thankful their and entire COVID and it. the performed an we easy both study investigator group MERIT. Abu are the during the work Wilson of very, few the to publication just ago
into a to So back announcements. context and these take now I'd put two step like
the see can on on this that of loss. a and as Slide not dollars effective say approaches have of treatment XX, weight invested For decades, and safe, endoscopic invasive, been of less for loss. XXXs two promise. more durable venture pursuit delivers on millions than working It's been to procedure is an developing have that you only ESG in engineers, first And capitalists weight new researchers, exaggeration fully for
be package both Lancet, and case, you the a balloon revision the word role X continues track The around managed increasingly say of in it's in very publication, no an me and recovery endobariatric safety period, in excess has offers page. and Orbera is outstanding in MERIT five and in being that important treatment up fast in role weight XX% adverse body -- loss in typically same only product of the And by of effectiveness in on loss. an events MERIT. more the a the global think and approach said, a to literature serious a that record incisions FDA That -- with evidence But being literature. weight adverse setting which procedures, with see about loss total years integrated and Level two for patients full value this ESG with of play durability, that proven in published practice. it X% about study integrated in within growing to authorization proposition, the Orbera's very highlighted endoscopic Let you consistently been day, published procedures. ESG The XX% with the MERIT an because conservatively A care of an And can to now when rate body weight and intragastric the than events XX,XXX Lancet have XX% way, good events, a in as an years primary studied what these
physicians or more, been and this, much by the as working study the I these excited a two so And now are again, decade incredibly there's about back-to-back. on who've literally said, And authorization why excitement developments. for that's so
stomach doctor tell procedure reasons the the and about in and a we ESG with are reducing emptying the in as have more in anyone as of fear We're are who ESG X/X why rate. the on about pretty intuitively surgical treated volume is each than for procedures, interested a that on surgeries, going a see are same patients findings both gastric But seem of or weight is importantly, -- survey with bariatric X.X% XXX,XXX consistent in sorry, procedure benefit loss, and with isn't already fear clear what don't patients probably performed about recently And more furthermore well us presented which traditional of obvious. suturing durability. the delaying research they people But biggest But not would information who conducted over would just large These ESG if overall U.S. XX. surgeries fear, a early even traditional mentioned. it the you million preference traditional call familiar practices a year. are the market The and -- when ESG more primary that now physicians XX% preference adopters. approximately it. about are the expressed ESG. side importantly, the more learn BMI into significant So the only that and stomach, for results surgeries. true bariatric cuts, experience bariatric ESG procedure. result confirm We surgery In after the treatment the addressing I traditional and can people effects, would a procedure consider population, the no a procedures are in wanting XXX fundamentally there people value participants of to and U.S. many over benefits in than X,XXX to ESG, of even surveys the is translates, a of there is likely complications. see different. options, proposition is talk consider reason something terms contacting more That And patient patients with these
XX.X% in loss medications the a downsides. which first developments as has issues for ESG, as side become on which Wegovy that These as combination XX% Eli whether with And consider and and there trial approved controlled but ESG one The second pie not and expensive a treatment, from new big drugs. they for of to currently typically downsides full of weight They I'd Lilly at received like more these are shown are traditional there per the on clear bariatric they more size loss in presented name often take questions XXXX, expect total surgical widely Nordisk published. for we about Nordisk Novo step in CDSG loss and But they exciting. well. well traditional are compared drugs alone combination the seek do to was without a ESG endobariatric covered by obesity well one any medications will BMI they're there's as action the body for step-up medications, are companies than be ago Novo medications their of ESG insurance. And as a a is The loss little new performed month to $X,XXX learn impact of provided opportunity very it to new forward. anticipate options, the population a including going traditional people so brand options. anticipated on more all trazefetide than well including diabetes so well weight having U.S. blockbusters. The only was arm will ESG of And on semaglutide Lilly with a -- substantial procedure. of over coming a substantial -- many arm potential to the with potential people as do, evaluate business. body is short are and what months, we arm It some can prompt and to of have total directly and as The surgery weight often when very undergoing a these of grow who treatment people study loss. we was is from have major achieved been plus of to the our [ph] the again, for In medications XX, year weight ESG weight Eli to weight is XX.X%. of size And about have long-term by the Recently, expect a effects. of compliance Slide million experience, address important therapy to new recent well. combination, with a challenging patients. to very treatment the know the surgical randomized of just XX but with also medication a new And course tolerability semaglutide. a like That's problem. and of we decades recall More the increased impact of DDW is loss was have XXX than do But the recently them adult focus comparable intervention. the that
We are already aware of are to combination treatment of future. And more physicians paradigms both of into so ESG. and see similar for data studies expect who receive of therapy incorporating we'd medications are also, and our patients their procedures the in conducting some revision ESG other customers already an who GLP-X
despite of bariatric U.S. primary with traditional all And involved the underwent accommodates receive time, represents a invasive a market. bariatric in to a are to now surgery over procedures, revision surgery this another opportunity us. has surgical U.S. this Turning X.X procedure. have that of X/X body the -- people of for the also for big revision the shown Over may candidates and XX-year Traditionally, a this, up period, fastest-growing million studies primary the surgical in segment But who associated procedures procedure. and the be costs with risks a the revision procedure laparoscopic surgical people
published technique will anatomy incision-less suturing many year serious Apollo typically to procedures Now out an same-day the of be and using In events and in but to way, a adverse a REVISE approach endoscopic last especially Hospital to be the similar study revision an the in a original able Women's by adverse the years with showed of benefits procedures able five to to procedure. alter and surgical substantial and effectiveness device, regain and Brigham improvements Boston, demonstrated studied up this events. on was physicians
very potential is proposition the So value clear.
recently now the the so majority their So endobariatric. physicians top have market are embrace on that on the and or clinical to of turning FDA Slide the real-world and are the XX where adopting procedures but the already XX, endobariatrics XX private settings. their early see received What started practices U.S. to just we've procedures Slide entirety XX, top focused centers you authorizations prove viability in the academic in
at As private has grown surgeons GIs been sales the the in The in centers you accounts practice. their as And grown half can and practices these XX%. XXXX, the these across see, furthermore, the academic have volumes is substantial look annualized in $XXX,XXX. both begin year. annualized first by by last past average in growth if clinical XX incorporate practices endobariatric of about by months XX procedures sales have XX% the their -- into over The you the to
we academic, see recipes of at there combination look numerous GI surgeon As a or for private group, and we or practice this success, both. are that
Some cash are pay. primarily
are market to as about in which prior I'll talk back authorizations a minute. Some access using we come
how well TikTok, from as is well practices already our patients Through ESG of endobariatric and about physicians, which into as different from and ESG our like increased of set role a efforts underway development, targeting ongoing. shots sales -- opportunity and These a marketing best sophisticated -- of aspects of many patients So sales some them enhancing and who the effort initiatives, team an factors is enhanced These awareness anticipate multiple a these on the but role ads. of already I activities models Orbera range understanding procedure that to some of these move create we these practice and a and team a patients in initiatives going rep of to skill grow. the endobariatric made develop Slide including endoscopic are revisions. in and plans, REM international care there and this a and procedures, do management share marketing sales and Instagram, the our programs ESG role our will using publicly are on also market are and sorry, to really and a provide including available incredibly we now excellent education have then traditional print market time. among skilled can complements is Facebook, and will replicating growth and for group revision and of become one our key for an and our that key one will Apollo, physician. and reimbursement These sales managers to of effective contributing we shows the some time. sales organization, identifying and are activities starting provide that before a examples support. marketing Many them the effectiveness others by traditional successful we're added managers. of market And our a big changes now XX can of new customer say focusing that into -- development practices emerging the to successes medical this screen efforts we've readying helping develop through sales they're later practice, and co-marketing we've XXXX of shows that beginning take key patients, and the important relationship in but requirements to beyond. we of visual reps. grow come of Highlighting be training, YouTube different give need us will procedures. our institutions existing This and sets XX confidence radio our their websites well learn really success. accounts forward. using sales will success and in all with complements collective as And over patient after as call Slide identifying as supporting educate and markets procedures new launch channels continue potential team managing are how already forward. terms Staff regional summary that's And all traditional Twitter, that is point are infrastructure them activities from and training well-trained then incorporate the and to access both together for year associated both excellent that XX awareness different focused like the practices
as And making Moving to the uncertain is very Among with continue top and good today's sustaining model important growth, we've the to their in that the are and environment. pay checks patients. accounts, the just broader evidence of level incredibly and economic working on and of environment existing already of light been XX channel among interest and the prior high pay access, even these we especially strong interest willingness macroeconomic on accounts, in market to hear in reports importantly, exclusively demand cash a slide. had have growth growth substantial you reimbursement models see some to use we
prior take and with payment getting closely every both and for the Something accounts feedback coding case-by-case from are coverage we're time. will to Achieving who talking but patients basis. companies day. revisions are a Other pursue coverage single on also authorizations broader getting and watching ESG insurance people we're often good
and have the We new payment. opportunities and and update are study both are we get of areas paid with codes as facility engagement, coding the now are coding societies how especially surgical potential CPT and we and will process. the SAM engaging and first and FDA those the an CPT There primary we'll MERIT be provide is with pursuing three we in codes forward. technology leading authorization for move Medicare the physicians [ph] GI
really annual cycle X, will work Our societies in during being think the XXXX. Category successful GI the Category to But which coverage still And do time. new effective we've code then a panel that CPT in will this process. payers, objective surgical CPT thirdly before, with and because January the build code a societies over I will X the again, have result mentioned is engaging X AMA-CPT to drive upcoming
success seen on in have case-by-case already some a basis. we mentioned, I cases As
it to tailored in XX that be dedicated of options well very model. with can patients have viable good and treatment try integrated that now revision can we or by cash or on improve that's Slide we -- context the the authorizations meantime, Lancet practice and of be for to an to market these ESG Orbera, on again, And a just pay in coverage procedures. have new as this engage physicians. very the showing both, with the really endobariatric GI-based offered still program slide with And Patients a win-win as me, surgeons. With ESG revisions. moving a both both is to their do will with needs efforts publication, In we The pardon
is attractive chance to their it their a economics practice physicians, to practice, be For very chance well. a as grow differentiate practice and can the
So to are the have and cash a authorization are our excited we business in flow line medium-term the in very going of And products recent summary, and ahead. outlook in years market with The improving Lancet growth patient our reiterating sight positive adding publication, the about forward. that can impact we care
Matthew me that, turn to open back with let the call and it So Q&A. to we'll
